RSS

acute bacterial skin and skin structure infections

Clinical-stage biopharmaceutical company, Motif Bio, has received acceptance from the US Food and Drug Administration (FDA) for the filing of its new drug application (NDA) for iclaprim to treat acute bacterial skin and skin structure infections more

News

The Food and Drug Administration (FDA) has granted fast track designation for Motif Bio’ iclaprim intravenous (IV) drug to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) more

News